Sales -12% and EBIT -2m vs. ABGSCe Weak performance in NW&FT, as market headwinds intensify Expect c...
14% EBIT beat on strong SC sales despite EE volume decrease Near-term headwinds from programme shut ...
Redeye raised its asset management assumptions following the strong report with CoinShares Physical ...
Redeye comments on G5’s Q3-results which saw somewhat softer topline than expected while gross margi...
Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in above our e...
NoHo Partners' Q3 2024 results missed Vara Research expectations on several items, but the guidance ...
Taaleri's Q3 2024 results were solid on an underlying basis and fairly in line with our estimates.
Redeye updates on Embracer ahead of Q2-results (due 14 November) where we expect another quarter wit...
Q3 numbers in line with estimates Guidance trimmed, but limited impact on estimates All share bid li...
Deliveries and sales in line, somewhat lower costs than expected Update on development studies and s...
Demand weak as expected, but improved by quarter-end Comps also ease in Q4, return to order growth l...
Redeye gives a brief comment on today’s news that the first patient has been included in the ELC-301...
Hanza rapporterade ett kvartal över Analysguidens förväntan.
MoveByBike Europe AB ("MoveByBike" eller "Bolaget") meddelade den 5 november 2024 att partnerskapet ...
Q3 results in-line, cash burn of DKK 27m Small new design win (~1k units), reiterates target of 4-6 ...
Redeye comments on Climeon’s Q3 figures that posted a variety of deviations from our estimates.
Q-linea continues improving the pipeline of prospects of various stages, from entering tenders to cl...
Sales -2%, adj. EBIT +4m vs. FactSet consensus Better EBIT largely driven by improved cost control E...
Taaleri reported recurring revenues of EUR 9.7m (-6% y/y), 4% below our estimate, mostly explained b...
Q3 EBITDA of 15.2m, in line with ABGSCe of USD 15.3m Small downward revisions to guidance Q3 much as...
